{"id":"W4385256763","doi":"10.1016/j.eururo.2023.06.006","title":"Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study","year":2023,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"Merck Sharp and Dohme","keywords":"Medicine; Axitinib; Sunitinib; Renal cell carcinoma; Pembrolizumab; Oncology; Internal medicine; Kidney cancer; Urology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003628359,0.001426443,0.003904671,0.0004543055,0.0007928265,0.001840804,0.0009331747,0.00183156,0.003634956],"category_scores_gemma":[0.002253784,0.0006474315,0.004493695,0.0006861309,0.0008796465,0.001894032,0.0005134203,0.004501825,0.001080232],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001502162,"about_ca_system_score_gemma":0.001380257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002105893,"about_ca_topic_score_gemma":0.003949507,"domain_scores_codex":[0.9987349,0.0006102579,0.00005836951,0.0001941649,0.0001224366,0.0002799576],"domain_scores_gemma":[0.9979568,0.0004209616,0.0006205587,0.0001990698,0.0001241133,0.0006785794],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9360573,0.0108737,0.006209949,0.0005493031,0.004875917,0.0001017228,0.0001435626,0.001554418,0.003392493,0.0000988317,0.002578431,0.03356435],"study_design_scores_gemma":[0.6089919,0.2924082,0.08220659,0.0001454281,0.006586609,0.0004153639,0.0002190978,0.001879296,0.002254807,0.0004482866,0.00434494,0.00009946567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882801,0.0057937,0.0003646504,0.0005006983,0.0002227214,0.0005895515,0.002183042,0.00007262947,0.001992996],"genre_scores_gemma":[0.990096,0.002395018,0.0004840847,0.001084352,0.000274891,0.0005174027,0.002840719,0.00004020657,0.002267499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003904671,"threshold_uncertainty_score":0.01918882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05018944831186409,"score_gpt":0.3036993253931792,"score_spread":0.2535098770813151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}